Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetyltrimethylammonium naproxenate is a defined 1:1 salt of the quaternary-ammonium antiseptic **cetrimonium** and the nonsteroidal anti-inflammatory drug **naproxen**. It has been marketed in Italy as **Nitens** in 0.223% local oral formulations, including mouthwash and oral-mucosal spray, for symptomatic inflammatory and painful conditions of the oral cavity and pharynx such as gingivitis, stomatitis, and pharyngitis, including after dental procedures. The naproxenate component provides local cyclooxygenase-mediated anti-inflammatory and analgesic activity, while the cetrimonium component has surfactant-mediated antiseptic activity. Published in-vitro studies reported rapid bactericidal activity against multiple oral and pharyngeal microorganisms and reduced adherence of selected bacterial-vaginosis-associated organisms to vaginal epithelial cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetyltrimethylammonium naproxenate.